Company Reports

Spirax Group has embedded its products and highly qualified engineers, who act as its salesforce, in customers’ industrial and commercial processes. Its large installed base of equipment creates recurring revenue through repair and maintenance as well as an upselling opportunity. Nearly half of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,500, and a further 35% from small improvement projects with short payback periods.

Spirax reported 6% adjusted organic operating growth in the first half, translating to 10 basis points of margin expansion to 19.8%. Management reiterated full-year guidance for mid-single-digit organic revenue growth and adjusted operating margin above 20.0%. Shares are trading 6% lower on Aug. 11.

Spirax Group has embedded its products and highly qualified engineers, who act as its salesforce, in customers’ industrial and commercial processes. Its large installed base of equipment creates recurring revenue through repair and maintenance as well as an upselling opportunity. Nearly half of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,500, and a further 35% from small improvement projects with short payback periods.

Spirax Group has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Its large installed base of equipment creates recurring revenue through repair and maintenance as well as an upselling opportunity. Nearly half of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,500, and a further 35% from small improvement projects with short payback periods.

Spirax Group confirmed its mid-single-digit organic revenue growth full-year guidance in a trading statement for the first four months of the year. Organic revenue grew in the midsingle digits through April 30, 2026, and the adjusted operating margin also improved on an organic basis year over year.

Spirax Group has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Approximately 50% of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,200, and a further 35% from small improvement projects with short payback periods. The recurring nature of Spirax's sales has allowed the group to enjoy resilience through the economic cycle compared with the more cyclical swings in customers’ capital-expenditure budgets, which are dependent on uncontrollable macroeconomic factors.

Spirax's adjusted operating profit grew 6% organically in 2025, translating to a 30-basis-point organic improvement in adjusted operating margin to 20.0%. The Watson-Marlow segment was the biggest contributor, with a 160-basis-point improvement.

Spirax Group has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Approximately 50% of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,200, and a further 35% from small improvement projects with short payback periods. The recurring nature of Spirax's sales has allowed the group to enjoy resilience through the economic cycle compared with the more cyclical swings in customers’ capital-expenditure budgets, which are dependent on uncontrollable macroeconomic factors.

Spirax provided a short trading update for the four months ended Oct. 31, 2025. No precise figures were given, but management confirmed its full-year outlook and announced that group organic revenue growth and margin are ahead of the first half. Shares are trading 3% higher intraday Nov. 13.

Spirax reported 1% organic revenue growth, but its adjusted operating profit grew by 7% organically during the first half. Results comfortably exceeded company-compiled consensus. Shares are trading 13% higher intraday.

Spirax kept its full-year guidance unchanged during a brief first-quarter trading update. However, foreign currency movements are expected to provide a 3% headwind on revenue and 6% on operating profit. Shares are trading 7% lower intraday on May 14.

Spirax Group has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Approximately 50% of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,200, and a further 35% from small improvement projects with short payback periods. The recurring nature of Spirax's sales has allowed the group to enjoy greater resilience through the economic cycle compared with the more cyclical swings in customers’ capital-expenditure budgets, which are dependent on uncontrollable macroeconomic factors.

Spirax reported 4% organic revenue growth during fiscal 2024, comfortably above global industrial production and broadly in line with company-compiled consensus. Shares are trading 2% lower intraday.

Shareholders in wide-moat Spirax will be happy with its brief third-quarter trading update, revealing organic sales growth across all three business segments year to date. While this isn’t the catalyst investors are looking for in a broader recovery, particularly across its Watson-Marlow business, which is the main driver behind the restoration of group profitability, it does suggest momentum is shifting favorably for the business. Full-year guidance is unchanged. Shares are trading 5% higher intraday, but still offer 30% upside to our GBX 9,650 fair value estimate, which we maintain.

We walked away from wide-moat Spirax’s capital markets day, confident in its fundamentals and path to restore EBIT margins between 22% and 23% in the medium term. Its long-term outlook remains robust and the group has proven in the past that it can comfortably outperform global industrial production growth, underpinned by fast-growing end markets and the small, but critical role its products have in customers’ production processes and decarbonization journeys. We view the slowdown in its recent performance, confined to a few sectors and China, as cyclical rather than structural. We keep our GBX 9,650 fair value estimate unchanged, presenting 25% upside for investors at current levels.

Spirax Group has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Approximately 50% of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,200, and a further 35% from small improvement projects with short payback periods. The recurring nature of Spirax's sales has allowed the group to enjoy greater resilience through the economic cycle compared with the more cyclical swings in customers’ capital-expenditure budgets, which are dependent on uncontrollable macroeconomic factors.

We’re lowering our fair value estimate in wide-moat Spirax Group by 9% to GBX 9,650 following its disappointing start to fiscal 2024 and reduction of its full-year guidance. Shares are trading 8% lower intraday, which we attribute to cyclical rather than structural reasons. We think there could be an element of conservatism baked into expectations by Spirax’s new executive team and believe its long-term outlook remains solid, underpinned by a recovery in its highest-margin Watson-Marlow segment. Shares are currently trading at an attractive 20% discount to our revised fair value estimate. We believe uncertainty surrounding the timing of a recovery in some of its material end markets and a somewhat untested new management team are weighing on the share price, which presents a buying opportunity for investors.

Investors in wide-moat Spirax-Sarco should favorably view its brief trading update that indicated low-single-digit organic revenue growth during the first four months of the fiscal year. Particularly pleasing is that all three of its operating segments recorded organic growth, an indicator that its Watson-Marlow division is likely through the worst of customer destocking from the biopharmaceutical sector and that the segment’s poor showing in fiscal 2023 was cyclical and not structural. Full-year guidance of mid- to high-single-digit organic revenue growth and low-double-digit organic operating profit growth was maintained. Spirax’s shares screen undervalued to our unchanged GBX 10,600 fair value estimate. We believe uncertainty surrounding the timing of a recovery in sales and its new management team are weighing on the share price, presenting a buying opportunity.

Spirax-Sarco Engineering has managed to embed its products and highly qualified engineers, who act as its salesforce, into customers’ industrial and commercial processes. Approximately 50% of the group’s sales are from recurring maintenance, with an average invoice value of GBP 1,200, and a further 35% from small improvement projects with short payback periods. The recurring nature of Spirax-Sarco's sales has allowed the group to enjoy greater resilience through the economic cycle compared with the more cyclical swings in customers’ capital-expenditure budgets, which are dependent on uncontrollable macroeconomic factors.

Wide-moat Spirax Group’s fiscal 2024 guidance of double-digit operating profit growth confirms our view that the challenges it faced in fiscal 2023, which saw organic revenue decline by 1%, were cyclical and not structural. Upbeat guidance for fiscal 2024 has ended the market's concerns that the destocking trend in fiscal 2023 reflected the group's long-term outlook, sending shares 11% higher. Our forecasts had incorporated a recovery in demand during fiscal 2024, broadly in line with management's expectations, and thus we maintain our GBX 10,600 fair value estimate. Following the jump in the share price on March 7, we view shares as fairly valued.